Oxaliplatin
As of the edition of 20 October 2026, Oxaliplatin is a small molecule: marketed, first approved in 2002 (US); no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2020
- Kind
- Small molecule
- Brand name
- Eloxatin
- First approved
- 9 August 2002 (US)
- Approvals on record
- 19 in 5 regions
- Holder of the most recent approval
- Sanofi; 6 holders in all
- Registered trials
- 1,594, 216 stopped early
- Disease areas
- Cancer; Digestive system; Hormones; Blood and lymph; Immune system; Urinary and reproductive
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 59 | 17 | 16 | 3 |
| Phase 1 | 218 | 122 | 50 | 30 |
| Phase 2 | 1,004 | 403 | 264 | 159 |
| Phase 3 | 292 | 104 | 97 | 23 |
| Phase 4 | 21 | 6 | 4 | 1 |
| All trials | 1,594 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Sanofi | Originator and Lead sponsor of trials | 1998 to now |
| Yakult Honsha | Applicant | 2005 to now |
| Pfizer | Applicant and Lead sponsor of trials | 2008 to now |
| Teva | Acquired holder and Later holder | 2009 to now |